Skip to main content

Day: February 4, 2021

Gen III Announces Closing of Debt Settlement and Grant of Stock Options

VANCOUVER, British Columbia, Feb. 03, 2021 (GLOBE NEWSWIRE) — Gen III Oil Corporation (“Gen III” or the “Company”) (TSX-V: GIII) (OTCQX: ISRJF) is pleased to announce that, further to its news release of November 24, 2020, it has settled $200,250 in debt (“Debt”) owing to certain directors of the Company, in exchange for 513,460 common shares (the “Shares”) at a deemed price of $0.39 per Share (the “Shares for Debt Transactions”).The Shares for Debt Transactions are each a “related party transaction” under applicable securities laws, and each director of the Company abstained from voting on the resolution approving the Shares for Debt Transaction that related to them. Each Shares for Debt Transaction is exempt from the formal valuation and minority approval requirements under Multilateral Instrument 61-101, as neither...

Continue reading

Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the pricing of its upsized initial public offering of 7,000,052 shares of common stock at a public offering price of $19.00 per share. The gross proceeds to Sensei from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sensei, are expected to be approximately $133.0 million. All of the shares are being offered by Sensei and are expected to begin trading on The Nasdaq Global Market on February 4, 2021 under the ticker symbol “SNSE.” In addition, Sensei has granted the underwriters a 30-day option to purchase up to an additional 1,050,007 shares of...

Continue reading

Landos Biopharma Announces Pricing of Initial Public Offering

BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Landos Biopharma. All of the shares of the common stock are being offered by Landos Biopharma.The shares are expected to begin trading on the Nasdaq Global Select Market on February 4, 2021 under the trading symbol of “LABP.” The offering is expected to close on February 8, 2021, subject to customary closing conditions. In addition, Landos Biopharma has granted...

Continue reading

Atotech Prices Initial Public Offering

BERLIN, Feb. 03, 2021 (GLOBE NEWSWIRE) — Atotech Limited (“Atotech”), a leading specialty chemicals technology company and a market leader in advanced electroplating solutions, has priced its initial public offering of 29,268,000 of its common shares at $17.00 per share. The shares are expected to begin trading on Thursday, February 4, 2021 on the New York Stock Exchange under the ticker symbol “ATC,” and the offering is expected to close on February 8, 2021, subject to customary closing conditions. The underwriters of the offering will also have a 30-day option to purchase up to an additional 4,390,200 common shares from certain affiliates of The Carlyle Group Inc. (the “selling shareholders”).Citigroup, Credit Suisse, BofA Securities and J.P. Morgan are lead book-running managers for the proposed initial public offering. Additional...

Continue reading

Avricore Health Announces $1.54 Million Financing

VANCOUVER, British Columbia, Feb. 03, 2021 (GLOBE NEWSWIRE) — AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) announces a non-brokered private placement of up to 7,000,000 units (“Units“) at a price of $0.22 per unit for gross proceeds of $1,540,000. (the “Private Placement“). The proceeds will be used for general working capital purposes.“We’ve built a strong business development program poised for significant growth across multiple business lines,” Said Hector Bremner, Avricore Health’s CEO. “With the resources generated through this placement, we can confidently take advantage of the opportunities in front of us and be completely focused on expanding HealthTab™ nationally, and internationally this year.”Each Unit consists of one common share and one transferrable share purchase warrant....

Continue reading

DCP Midstream Joins The Environmental Partnership

DENVER, Feb. 03, 2021 (GLOBE NEWSWIRE) — Today, DCP Midstream (NYSE: DCP) announced it has joined The Environmental Partnership, a growing coalition of companies in the U.S. oil and natural gas industry committed to continuously improving the industry’s environmental performance by taking action in operations; building upon our knowledge; and fostering collaboration.Natural gas is a critical component of our nation’s energy future and transition. As one of the largest natural gas processors in the U.S., DCP plays a critical role in the energy value chain that drives our society. The company believes that industry has a responsibility to innovate and has a role to play in our nation’s clean energy future.“DCP Midstream is committed to adopting industry leading best-practices and technologies focused on reducing our environmental...

Continue reading

Correction to Press Release: Extendicare Announces Timing of 2020 Fourth Quarter Results and Year End Results and Conference Call

MARKHAM, Ontario, Feb. 03, 2021 (GLOBE NEWSWIRE) — The release dated January 25, 2021, contained a clerical error: the date of the planned release of the financial results for the fourth quarter and year ended December 31, 2020, should have been Thursday, February 25, 2021 (instead of Wednesday, February 24, 2021) and the date of the conference call to discuss the results should have been February 26, 2021 (instead of February 25, 2021).The corrected release reads:Extendicare Announces Timing of 2020 Fourth Quarter Results and Year End Results and Conference CallExtendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the fourth quarter and year ended December 31, 2020 after market close on Thursday, February 25, 2021. A conference call hosted by Michael Guerriere,...

Continue reading

FTI Consulting Construction Solutions Practice Appoints Senior Professionals to Enhance Construction Dispute and Litigation Expertise

HONG KONG, Feb. 03, 2021 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that Nick Adams has been appointed as a Senior Managing Director and Johnny Chao as an Associate Director in the Construction Solutions practice, based in Hong Kong.Mr. Adams and Mr. Chao join FTI Consulting from Aspect Asia. Their appointments enhance FTI Consulting’s bench of construction expertise, which includes industry leaders who understand technical, business, regulatory and legal matters and are seasoned in giving expert testimony.“I am delighted to welcome Nick and Johnny to the Construction Solutions team,” said Graham McNeill, Global Leader of the Construction Solutions practice at FTI Consulting. “Nick brings with him a wealth of experience in both the Hong Kong and international markets. Having worked across from Nick as a...

Continue reading

CMC Materials Reports Record Revenue for the First Quarter of Fiscal 2021 and Raises Full Year Guidance

Record Revenue of $287.9 Million, 1.7% Higher than Last Year and 5.0% Higher Sequentially Due to Strong Growth in CMP Slurries and CMP PadsDiluted Earnings Per Share (EPS) of $1.07; Adjusted Diluted EPS1of $1.92, Flat Compared to Last YearExpecting Revenue for Second Quarter Fiscal 2021 to be Up Low Single Digits SequentiallyRaises Full Fiscal Year 2021 Adjusted EBITDA to be Between $367 Million and $387 MillionAURORA, Ill., Feb. 03, 2021 (GLOBE NEWSWIRE) — CMC Materials, Inc. (Nasdaq: CCMP), a leading global supplier of consumable materials primarily to semiconductor manufacturers, today reported financial results for its first quarter of fiscal 2021, which ended December 31, 2020.Key Highlights for the First QuarterStronger demand in Electronic Materials, which represents over 80% of the company’s revenue, drove a revenue increase...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.